Scientific leadership profile

Major research achievements in the field of viral immunology and pathogenesis:

  1. Discovery of physiological plasticity of T cell response to viral infection – evidence that CD8+ T cells deficient mice eliminate the virus via the compensatory response mediated by CD4+ T cells (J. Virol. 64:5457-5464, 1990
  2. Evidence that CD4 cells and IFN-gamma are necessary for preventing the horizontal transmission of MCMV infection. (J. Exp. Med. 169:1199-1212, 1989; J. Virol. 66:1977-1984, 1992).
  3. Evidence that antiviral antibodies are not required for the resolution of primary infection and the establishment and maintenance of CMV latency, but play a key role in limiting recurrent herpesvirus infection (J. Exp. Med. 179:1713-1717, 1994)
  4. Evidence that CD8+ and CD4+ T cell subsets, IFN-gamma as well as NK cells contribute in a hierarchical and redundant fashion to immunosurveillance of MCMV latency and prevention of recurrent infection (J. Exp. Med. 188:1047-1054, 1998)
  5. Evidence for the role in vivo of herpesviral immunoevasins involved in the downmodulation of MHC class I molecules (J. Exp. Med. 190:1285-1295, 1999)
  6. First discovery that CMV prevents NK cell activation by down-modulating cellular ligands for the activating NK cell receptor NKG2D  and characterization of several other viral inhibitors of cellular NKG2D ligands (Nat. Immunol. 3:529-535, 2002; J. Virol. 79:2920-30, 2005; J. Exp. Med. 201:211-220, 2005; J. Exp. Med. 203:1843-50, 2006)
  7. Establishment of the MCMV model to study CMV infection in the developing CNS (J. Exp. Med. 205:423-35, 2008; J. Virol. 82(24):12172-80, 2008)
  8. The newly discovered inhibitory receptor expressed on human NK cells and some subsets of T cells (Proc. Natl. Acad. Sci. U S A. 106(42):17858-63, 2009)
  9. Evidence that MCMV m04 protein is essential for activation of NK cells via Ly49P (J. Exp. Med. 206(3):515-23, 2009)
  10. First evidence that ‘missing-self’ dependent NK cell activation plays a role in virus control and characterization of MCMV immunoevasion of this effector mechanism (J. Exp. Med. 207(12):2663-73, 2010)